pdufa.bio
Home › CRL letters › February 2026

FDA complete response letters, February 2026

Page updated ·next FDA decision on the calendar ·Data as of Nov 10, 2026 12:55 AM ET

The FDA's public release of complete response letters holds 6 letters dated February 2026 (openFDA, last updated 2026-08-26). Of the 27 FDA decisions on PDUFA goal dates pdufa.bio tracked in February 2026, 6 were Complete Response Letters.

Released by the FDA, dated February 2026 · 6

Letter dateCompanyApplicationopenFDA statusLetter
2026-02-27Fresenius Kabi USA, LLCNDA 214610Unapprovedletter (PDF)
2026-02-27Ferring Pharmaceuticals Inc.BLA 761253Unapprovedletter (PDF)
2026-02-27Fresenius Kabi USA, LLCNDA 215818Unapprovedletter (PDF)
2026-02-26Amphastar Pharmaceuticals, Inc.BLA 761403Unapprovedletter (PDF)
2026-02-13Disc Medicine, Inc.NDA 220707Unapprovedletter (PDF)
2026-02-07REGENXBIO, Inc.BL 125840Unapprovedletter (PDF)

Complete Response Letters among decisions pdufa.bio tracked · 6

FDA actionTickerDrugSource
2026-02-15IRONBitopertindecision page
2026-02-13IRONBitopertin - (BEACON)decision page
2026-02-09RGNXclemidsogene lanparvovec (RGX-decision page
2026-02-08RGNXRGXdecision page
2026-02-02AQSTAnaphylmdecision page
2026-02-01PHARsource-verifieddecision page
A Complete Response Letter is the FDA's notice that it will not approve an application in its current form; it is not a permanent rejection, and the sponsor can resubmit. The two counts come from different records and are not added together. ← January 2026 · March 2026 → · all released letters · every CRL decision we tracked